Thoretec Pipeline: HeartMate III Fully Magnetic LVAD Trial Set For 2012
This article was originally published in The Gray Sheet
Thoratec plans to start a clinical trial at the end of 2012 for its next-generation HeartMate III left ventricular assist device with a magnetically levitated rotor designed to help reduce the risk of pump-related clots, bleeding and strokes.
You may also be interested in...
Thoratec reported a near 10 percent year-over-year decline in revenue in the second quarter; physicians have become more selective about which patients to implant with a HeartMate II ventricular assist device, the firm says. The company is looking to next-generation of HeartMate products as well as the technology it acquired in the Apica deal to help it return to growth.
Thoratec’s virtual monopoly in the LVAD market is about to end with the anticipated launch of HeartWare’s system this month or next, but executives are not displaying major concern.
Thoratec’s miniature rotary blood pump LVAD is something Dick Cheney has “gotten used to living with,” the former U.S. vice president said Oct. 5 at the Cleveland Clinic’s annual Medical Innovations Summit in Cleveland, during an interview with ABC News anchor Bob Woodruff.